Biocryst Pharmaceuticals (BCRX) EPS (Diluted) Growth (1y) (2014 - 2026)
Biocryst Pharmaceuticals (BCRX) EPS (Diluted) Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | -304.28% |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 1.28% |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -15.70% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 13.47% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 30.20% |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | 385.28% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 1,178.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,178.44% |
| Mar 31, 2026 | -2,004,393.63% |
| Dec 31, 2025 | 967.62% |
| Sep 30, 2025 | 186.49% |
| Jun 30, 2025 | 137.67% |
| Mar 31, 2025 | 100.09% |
| Dec 31, 2024 | 59.64% |
| Sep 30, 2024 | 64.42% |
| Jun 30, 2024 | 84.59% |
| Mar 31, 2024 | 39.32% |
| Dec 31, 2023 | 16.54% |
| Sep 30, 2023 | 16.54% |
| Jun 30, 2023 | -25.60% |
| Mar 31, 2023 | 29.50% |
| Dec 31, 2022 | -287.69% |
| Sep 30, 2022 | 99.93% |
| Jun 30, 2022 | 99.87% |
| Mar 31, 2022 | -10.70% |
| Dec 31, 2021 | 75.20% |
| Sep 30, 2021 | -125,601.88% |